What is Human Longevity?
Established in 2013, Human Longevity, Inc. operates as a global leader in the field of longevity medicine. By integrating comprehensive genomic sequencing with advanced clinical data, the company provides actionable health intelligence designed to extend the human healthspan. HLI's market position is defined by its commitment to transforming reactive healthcare into a proactive, data-driven discipline. The company serves a diverse clientele, ranging from research institutions to individuals seeking personalized health optimization, leveraging its deep expertise in bioinformatics and molecular diagnostics to maintain a competitive edge in the rapidly evolving biotechnology landscape.
How much funding has Human Longevity raised?
Human Longevity has raised a total of $370.8M across 5 funding rounds:
Series A
$80M
Series B
$220M
Other Financing Round
$30M
Debt
$1M
Series B
$39.8M
Series A (2014): $80M with participation from Synthetic Genomics, Daniel Curran, Celgene, Draper Fisher Jurvetson (DFJ), and Illumina
Series B (2016): $220M led by Illumina, GE Ventures, and Celgene
Other Financing Round (2019): $30M supported by Emerging Technology Partners
Debt (2020): $1M featuring PPP
Series B (2024): $39.8M backed by Emerging Technology Partners, Panacea Ventures, and TVM Capital Healthcare Partners
Key Investors in Human Longevity
Illumina
A global leader in sequencing and array-based solutions for genetic and genomic analysis, providing the foundational technology for advanced diagnostic research.
Draper Fisher Jurvetson (DFJ)
A prominent venture capital firm with a global network, focused on backing extraordinary entrepreneurs and transformative technologies across multiple high-growth sectors.
TVM Capital Healthcare Partners
A specialized private equity firm focused on emerging markets, providing growth capital to healthcare services, digital health, and medical diagnostic companies.
What's next for Human Longevity?
With the recent influx of capital, Human Longevity is poised to accelerate its strategic growth initiatives. The company is prioritizing the scaling of its U.S. operations while simultaneously executing a targeted expansion into the Kingdom of Saudi Arabia and Southeast Asia. This geographic diversification is expected to broaden the reach of its precision medicine services, tapping into emerging demand for high-end diagnostic solutions. By strengthening its international presence and continuing to invest in its core genomic technologies, HLI aims to solidify its status as the premier provider of longevity-focused medical interventions on a global scale.
See full Human Longevity company page
